Might as well model a billion shares outstanding g
Post# of 154851
(Total Views: 632)
Posted On: 04/09/2020 5:29:56 PM
Might as well model a billion shares outstanding going forward. It's just a matter of time.
They are handing out stock like drunk sailors. They repriced warrants lower as recently as February. Have big payments due Samsung this year. Milestone payments to various entities and on and on and on.
They need a massive raise and injection of cash. I am personally hoping for a buyout. I know this won't be popular. But we are going to have a massive overhang of stock liquidations, major execution risk, insufficient funds to build inventories and skyrocketing clinical trial expenses. GvHD has been delayed and per filing, "We will require a significant amount of additional capital to complete the foregoing clinical trials for HIV and complete our BLA submission, as well as to advance our trials in the oncology and immunology space, including, but not limited to triple-negative breast cancer, basket cancer indications, GvHD, NASH, COVID-19. See “Liquidity and Capital Resources” below."
Then add to that the risk of an FDA rejection for the BLA (no reason to believe this will happen but it is a risk) and/or continued FDA delays and moving targets. Well, you get the point. We all love the idea of taking over the world but we often forget about the numerous risks.
Now before everyone jumps off the deep end about an early buyout, if the deal was structured well, we could still participate in the upside via the issuance of CVR's. Granted, it wouldn't be as profitable, but I'm fine with a triple (baseball) as opposed to a homerun.
I'm out of posts for the day. Hope everyone enjoys the long weekend.
They are handing out stock like drunk sailors. They repriced warrants lower as recently as February. Have big payments due Samsung this year. Milestone payments to various entities and on and on and on.
They need a massive raise and injection of cash. I am personally hoping for a buyout. I know this won't be popular. But we are going to have a massive overhang of stock liquidations, major execution risk, insufficient funds to build inventories and skyrocketing clinical trial expenses. GvHD has been delayed and per filing, "We will require a significant amount of additional capital to complete the foregoing clinical trials for HIV and complete our BLA submission, as well as to advance our trials in the oncology and immunology space, including, but not limited to triple-negative breast cancer, basket cancer indications, GvHD, NASH, COVID-19. See “Liquidity and Capital Resources” below."
Then add to that the risk of an FDA rejection for the BLA (no reason to believe this will happen but it is a risk) and/or continued FDA delays and moving targets. Well, you get the point. We all love the idea of taking over the world but we often forget about the numerous risks.
Now before everyone jumps off the deep end about an early buyout, if the deal was structured well, we could still participate in the upside via the issuance of CVR's. Granted, it wouldn't be as profitable, but I'm fine with a triple (baseball) as opposed to a homerun.
I'm out of posts for the day. Hope everyone enjoys the long weekend.
(3)
(8)